The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters

From The Hill

It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.

Source Author
Author: Source Author

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *